Revista médica de Chile
-
Revista médica de Chile · Nov 2020
[Reliability and construct validity of SF-12 to measure health related quality of life in Chilean subjects].
Health-Related Quality of Life (HRQoL) is understood as a multidimensional variable, mostly measured using the SF-12 questionnaire. However, this measurement doesn't always replicate the factorial structure theoretically expected, hindering potential conclusions. ⋯ The practical importance of these results highlight the need to measure HRQoL using more extensive scales.
-
Revista médica de Chile · Nov 2020
Review[Anti-inflammatory therapies for SARS-COV2 infection from a hematological perspective].
The pathophysiology of the inflammatory profile induced by SARS-COV2 infection has similarities with conditions of immune system activation with cytokine release such as hemophagocytic syndrome and some cases of acute graft-versus-host disease. There are encouraging results of clinical studies, performed with increasingly better methodological quality, supporting the use of targeted and specific anti-inflammatory therapy in selected groups of patients with COVID-19 with severe inflammation. In this review we describe the inflammatory pathophysiology of the disease and the recent findings about its treatment.
-
Revista médica de Chile · Nov 2020
Clinical features of 47 patients infected with COVID-19 admitted to a Regional Reference Center.
During the first pandemic wave, Covid-19 reached Latin America cities. ⋯ In our regional Center, patients admitted with COVID-19 had usual risk factors and had a prolonged stay. Hospital mortality was associated with immunosuppression and ICU admission.
-
Revista médica de Chile · Nov 2020
Case ReportsTrametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case.
MEK- and BRAF-inhibitors trametinib and dabrafenib are successfully used for BRAF-mutated, metastasizing melanoma, but these compounds may induce side effects. We report a 50 years old female with BRAF-mutated metastasizing melanoma who received trametinib (2 mg/d) and dabrafenib (200 mg/d) after using interferon without benefit. Shortly after starting trametinib/dabrafenib, she experienced an inability to abduct the left eye. ⋯ She could not eat or drink during four days prior to admission. The patient suspected an adverse effect of trametinib/dabrafenib and discontinued it 2 days prior to admission. Thereafter, she experienced an almost complete remission of the deficits except for ocular muscle weakness and visual impairment.
-
Revista médica de Chile · Nov 2020
Case Reports[Lupus erythematosus associated with erythema multiforme or Rowell's syndrome. Report of one case].
Rowell's syndrome is characterized by an association of lupus erythematosus and erythema multiforme, with distinctive laboratory findings. Its treatment is similar to lupus. We report a 16-year-old female presenting with skin lesions, laboratory and histology consistent with this entity. Because of the spread of cutaneous involvement and development of epidermal detachment, she required therapy with intravenous corticosteroids and gamma globulin.